Vor Biopharma Inc VOR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 6:44 PM EDT
1.82quote price arrow up+0.08 (+4.60%)
Volume
2,696
Close
1.74quote price arrow down-0.14 (-7.45%)
Volume
283,947
52 week range
1.62 - 5.70
Loading...
  • Open1.86
  • Day High1.87
  • Day Low1.73
  • Prev Close1.88
  • 52 Week High5.70
  • 52 Week High Date06/08/23
  • 52 Week Low1.62
  • 52 Week Low Date11/21/23

Key Stats

  • Market Cap118.695M
  • Shares Out68.22M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta-0.24
  • YTD % Change-22.67

KEY STATS

  • Open1.86
  • Day High1.87
  • Day Low1.73
  • Prev Close1.88
  • 52 Week High5.70
  • 52 Week High Date06/08/23
  • 52 Week Low1.62
  • 52 Week Low Date11/21/23
  • Market Cap118.695M
  • Shares Out68.22M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta-0.24
  • YTD % Change-22.67

RATIOS/PROFITABILITY

  • EPS (TTM)-1.75
  • P/E (TTM)-0.99
  • Fwd P/E (NTM)-1.20
  • EBITDA (TTM)-122.499M
  • ROE (TTM)-58.74%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vor Biopharma Inc

 

Profile

MORE
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The...
Matthew Patterson
Non-Executive Independent Chairman of the Board
Robert Ang M.D.
President, Chief Executive Officer, Director
Nathan Jorgensen Ph.D.
Chief Financial Officer
Address
100 Cambridgepark Drive, Suite 101
Cambridge, MA
02140
United States

Top Peers

SYMBOLLASTCHG%CHG
CTXR
Citius Pharmaceuticals Inc
0.7165-0.0508-6.6206%
NVCT
Nuvectis Pharma Inc
6.71+0.12+1.82%
PROK
ProKidney Corp
2.71+0.18+7.11%
ANVS
Annovis Bio Inc
12.74+0.86+7.24%
GNLX
Genelux Corp
3.45-0.03-0.86%